NCT06315400View on ClinicalTrials.gov

Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections

PHASE4RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Influenza, HumanAcute Respiratory InfectionCommon Cold
Interventions
DRUG

Ingavirin®

60 mg/day for 5 days

DRUG

Placebo

1 capsule/day for 5 days

Trial Locations (3)

150000

RECRUITING

"GBOU VPO Yaroslavl State Medical University of Ministry of Health of Russian Federation", Yaroslavl

Unknown

RECRUITING

"GBOU VPO Rostov State Medical University of Ministry of Health of Russian Federation", Rostov-on-Don

RECRUITING

"GBOU VPO Siberia State Medcial University of Ministry of Health of Russian Federation", Tomsk

All Listed Sponsors
lead

Valenta Pharm JSC

INDUSTRY